|
業務類別
|
Biotechnology |
|
業務概覽
|
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion. |
| 公司地址
| 1751 River Run, Suite 400, Fort Worth, TX, USA, 76107 |
| 電話號碼
| +1 817 887-8455 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.actuatetherapeutics.com |
| 員工數量
| 10 |
| Mr. Daniel M. Schmitt |
President, Chief Executive Officer and Director |
美元 400.00K |
08/04/2025 |
| Mr. Paul J. Lytle |
Chief Financial Officer and Principal Accounting Officer |
美元 210.00K |
08/04/2025 |
| Dr. Andrew P. Mazar, PhD |
Chief Operating Officer |
美元 450.00K |
08/04/2025 |
|
|
| Mr. Daniel M. Schmitt |
President, Chief Executive Officer and Director |
08/04/2025 |
| Mr. Jason A. Keyes |
Independent Director |
08/04/2025 |
| Dr. Aaron G.L. Fletcher, PhD |
Chairman of the Board |
08/04/2025 |
| Mr. Todd S. Thomson |
Independent Director |
08/04/2025 |
| Dr. Dan Zabrowski, PhD |
Independent Director |
08/04/2025 |
| Dr. Roger Sawhney, M.D. |
Independent Director |
08/04/2025 |
| Ms. Amy L. Ronneberg |
Independent Director |
08/04/2025 |
|
|
|
|
